Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study

•A population-based longitudinal cohort study of 268 cladribine treated patients.•The median follow-up time was 35 months and 80% completed two courses of cladribine.•Cladribine reduced the annual relapse rate by 85% compared with the year before.•Adverse events, reported by 16% of the patients, were usually mild or moderate.•11% discontinued cladribine; 3% owing to adverse effect and 5% to disease activity.